Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 10/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30074414 | 1.00 | ABCG2 (0.47) | ABCG2FFAR1PPARDKDM4EABCB1 | |
| SCHEMBL30074393 | 0.85 | ABCG2 (0.41) | ABCG2FFAR1KDM4EABCB1 | |
| SCHEMBL25496279 | 0.85 | ABCG2 (0.41) | ABCG2FFAR1KDM4EABCB1 | |
| SCHEMBL25496276 | 0.84 | ABCG2 (0.42) | ABCG2FFAR1KDM4EABCB1 | |
| SCHEMBL30074358 | 0.84 | ABCG2 (0.42) | ABCG2FFAR1KDM4EABCB1 | |
| SCHEMBL24894484 | 0.82 | FFAR1 (0.51) | FFAR1PPARDKDM4EPPARGPPARA | |
| SCHEMBL24894488 | 0.80 | ABCG2 (0.40) | ABCG2FFAR1KDM4EABCB1PPARG | |
| SCHEMBL29197614 | 0.78 | ABCG2 (0.42) | ABCG2KDM4EABCB1 | |
| SCHEMBL20682706 | 0.78 | KMT2A (0.56) | ABCG2 | |
| SCHEMBL13554687 | 0.78 | KMT2A (0.56) | ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117915956-A | M6PR cell surface receptor binding compounds and conjugates | 利西亚治疗公司 | 2024-04-19 | — | — | CN | disclosed |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| CN-115315263-A | Cell surface receptor binding compounds and conjugates | 利西亚治疗公司 | 2022-11-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | M6PR, ASGR1, IGF2R | ABCG2 675/4885FFAR1 233/4885PPARD 3521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.